GLP-1 Weight Loss Injections
GLP-1: What Women Need to Know (and what is often missing)
But alongside the results, there is often uncertainty. What exactly are these drugs? How do they work? And what happens when the treatment ends?
What are GLP-1 medications?
GLP-1 receptor agonists (such as semaglutide or tirzepatide) were originally developed to treat Type 2 diabetes. They work by mimicking a natural hormone (Glucagon-like peptide-1) that targets areas of the brain that regulate appetite and food intake.
Specifically, they:
- Regulate blood sugar: By stimulating insulin secretion in response to meals.
- Delay gastric emptying: Slowing down how quickly food leaves your stomach, which signals fullness.
- Reduce appetite: Communicating directly with the hypothalamus to lower hunger signals.
Who can access them?
In the UK, access through the NHS is currently restricted to specific tiers of weight management services. They are typically prescribed to people with:
- Obesity: Defined as a BMI 30, or 27 with weight-related comorbidities (like hypertension).
- Clinical supervision: Use is intended alongside a reduced-calorie diet and increased physical activity.
Many women now access these medications privately. However, without a structured nutrition plan, there is a risk of losing weight in a way that compromises long-term health.
They are not just a "quick fix"
These medications are powerful metabolic tools, but they are still medical interventions. Because they suppress appetite so effectively, many users unintentionally fall into a "malnutrition of obesity."
Without proactive guidance, common issues include:
- Sarcopenia (Muscle Loss): Rapid weight loss often includes significant loss of lean muscle mass.
- The Protein Gap: Insufficient protein intake accelerates muscle loss, which is particularly dangerous during perimenopause and menopause when muscle preservation is already a challenge.
- Nutrient Deficiencies: Eating very small volumes of food makes it harder to hit targets for Vitamin B12, Iron, and Calcium.
What happens when you stop?
This is the part that is often missed in the marketing. Clinical trials (such as the STEP 4 trial) show that many patients regain a significant portion of their lost weight within a year of stopping the medication.
This is not a "failure of willpower." It is a biological reality. When the medication is withdrawn, the appetite signals return, often more intensely. If long-term metabolic habits and muscle-strengthening routines were not established during the treatment, the body is primed to regain fat.
A more supportive approach
If you are using or considering these medications, the focus must shift from "eating less" to "nourishing more." A successful strategy includes:
- Prioritising Protein: To protect muscle mass and metabolic rate.
- Resistance Training: To signal to your body to keep muscle while losing fat.
- Habit Formation: Using the "quiet brain" the medication provides to build a sustainable relationship with food.
- The Exit Strategy: Having a clear plan for how to maintain your new set-point if or when you choose to stop the injections.
You do not have to navigate this alone
This is a big step, but with the right support, it becomes much more than just a number on a scale, it becomes a foundation for the next chapter of your health.
If you want honest, evidence-based guidance without judgment, I am here to help.
References:
Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. (The STEP 1 Trial establishing efficacy).
PURENERGY Nutrition
Supporting your health at every stage.
Build on science, made for You.